In this regard, a multicenter phase III Italian clinical trial (HOrmonal BOne Effects, HOBOE) randomized 1065 premenopausal women with hormone-receptor-positive early BC to receive adjuvant triptorelin in addition to tamoxifen (TT), letrozole (TL) or letrozole + zoledronate (TLZ). The gene discussed is NR4A1; the disease is breast cancer.